New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
15:22 EDTPPHM, ABM, TEA, LDR, SURG, GEFCompanies reporting After the Market Close on Monday, December 10
Notable companies reporting after the closing bell on Monday include ABM Industries (ABM), Greif (GEF), Landauer (LDR), Peregrine Pharmaceuticals (PPHM), Synergetics (SURG), and Teavana Holdings (TEA).
News For ABM;GEF;LDR;PPHM;SURG;TEA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
13:51 EDTPPHMPotential Ebola patient being treated at UC Davis Medical Center, KCRA says
Subscribe for More Information
January 25, 2015
13:57 EDTPPHMUK nurse make full recovery from Ebola, WSJ says
Subscribe for More Information
January 21, 2015
09:16 EDTGEFGreif sees FY17 sales $4.32B-$4.407B
Greif forecasts net sales to grow 2.0-3.0% in both 2016 and 2017. Sees FY17 gross profit margin 20%, up from 19.1% in FY14. Sees FY17 EBITDA ex-items $570M-$579M.
09:15 EDTGEFGreif sees FY15 EBITDA ex-items $429.9M
Subscribe for More Information
January 20, 2015
09:54 EDTGEFGreif to host investor day
Investor Day to be held in New York on January 21 at 9 am. Webcast Link
January 16, 2015
10:01 EDTGEFOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:31 EDTPPHMPeregrine announces Ohase II clinical data of bavituximab with sorafenib
Peregrine Pharmaceuticals announced the presentation of clinical data related to the company's immuno-oncology development program and its lead investigational immunotherapy drug candidate bavituximab at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. In this single-center, single-arm, open-label investigator-sponsored trial, 38 patients with advanced HCC received bavituximab weekly and sorafenib twice daily until disease progression or toxicity. Data show that the combination of bavituximab and sorafenib is associated with an improved time to progression of 6.7 months, a disease specific survival of 8.7 months, a disease control rate of 58% and a 4-month progression-free survival of 62%. Two patients achieved a partial response according to Response Evaluation Criteria In Solid Tumors. The secondary endpoint of median overall survival was 6.2 months. The combination of bavituximab and sorafenib was well-tolerated in patients with advanced HCC with no indications of autoimmune adverse events that have been seen with other checkpoint immunotherapies.
06:26 EDTGEFGreif downgraded to Underperform from Market Perform at BMO Capital

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use